Symbiotic Capital Raises $600M

Over $600 million has been gathered by Symbiotic Capital, a new worldwide life science lending business. Businesses in the biotech, medical technology, synthetic biology, and other healthcare industries will get credit alternatives from Symbiotic.

The California company is connected to Bellco Capital, an investment business established in Los Angeles by biotech innovator Arie Belldegrun, M.D., who additionally helped build Vida Ventures, Allogene Therapeutics, and Kite Pharma.

Symbiotic co-chair Belldegrun commented: “The life science industry continues to experience unprecedented productivity, innovation and scientific discovery as biotechnology and technology converge.”

They continued: “As the cost to research, develop and commercialize innovative therapeutics, devices, tools and other products has increased substantially throughout the sector, credit has become an increasingly important financing tool for established healthcare enterprises. With Symbiotic Capital, we have designed a science-first credit platform to fuel those endeavors.”